Orphan Drugs
07-04-2010 |
21:17 hs.
The European Medicines Agency granted orphan drug status for Sanofi-Aventis SA for tuberculosis drug, Rifapentine.
06-21-2010 |
16:35 hs.
Allos Therapeutics Inc. announced that the European Medicines Agency granted orphan drug status for experimental drug Pralatrexate, indicated to treat cutaneous T-cell lymphoma (CTCL)
Known as Folotyn
05-19-2010 |
17:08 hs.
Allos Therapeutics Inc. cancer drug Pralatraxate, received orphan drug status to treat advanced or metastatic transitional cell carcinoma of the urinary bladder.
Orphan Drug Status
06-03-2009 |
13:40 hs.
Biotechnology NeurogesX Inc. announced that the Food and Drug Administration granted orphan drug status for Qutenza drug to treat neuropathic pain in patients with postherpetic neuralgia.
10-15-2008 |
12:48 hs.
07-07-2008 |
12:31 hs.
03-06-2008 |
13:30 hs.
ActivBiotics said the FDA has granted Orphan Drug Designation for M40403 for the prevention of chemotherapy-induced oral mucositis (OM) in cancer patients
03-04-2008 |
12:50 hs.
FDA grants Mpex orphan drug designation for its proprietary levofloxacin aerosol formulation, MP-376, designed to treat pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis
